These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37954886)

  • 1. Evaluating Glycemic Control Efficacy and Safety of the Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron in Type 2 Diabetes Patients: A Systemic Review and Meta-Analysis.
    Fatima H; Rangwala HS; Mustafa MS; Shafique MA; Abbas SR; Rizwan A; Fadlalla Ahmed TK; Arshad A
    Diabetes Metab Syndr Obes; 2023; 16():3567-3578. PubMed ID: 37954886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Saxena AR; Frias JP; Brown LS; Gorman DN; Vasas S; Tsamandouras N; Birnbaum MJ
    JAMA Netw Open; 2023 May; 6(5):e2314493. PubMed ID: 37213102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.
    Karakasis P; Patoulias D; Pamporis K; Stachteas P; Bougioukas KI; Klisic A; Fragakis N; Rizzo M
    Metabolism; 2023 Dec; 149():155710. PubMed ID: 37852529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus.
    Ono R; Furihata K; Ichikawa Y; Nakazuru Y; Bergman A; Gorman DN; Saxena AR
    Diabetes Obes Metab; 2023 Mar; 25(3):805-814. PubMed ID: 36433713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.
    Saxena AR; Frias JP; Gorman DN; Lopez RN; Andrawis N; Tsamandouras N; Birnbaum MJ
    Diabetes Obes Metab; 2023 Oct; 25(10):2805-2814. PubMed ID: 37311722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.
    Li WX; Gou JF; Tian JH; Yan X; Yang L
    Curr Ther Res Clin Exp; 2010 Aug; 71(4):211-38. PubMed ID: 24688145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial.
    Saxena AR; Gorman DN; Esquejo RM; Bergman A; Chidsey K; Buckeridge C; Griffith DA; Kim AM
    Nat Med; 2021 Jun; 27(6):1079-1087. PubMed ID: 34127852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel approach to exploit Small-Molecule glucagon-like Peptide-1 receptor agonists with high potency.
    Wang X; Yun Y; Chen L; Guo S; Niu B; Fang J; Yuan Q; Shen J; Xie X; Wang K
    Bioorg Med Chem; 2024 Jun; 107():117761. PubMed ID: 38795571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
    Weibel S; Rücker G; Eberhart LH; Pace NL; Hartl HM; Jordan OL; Mayer D; Riemer M; Schaefer MS; Raj D; Backhaus I; Helf A; Schlesinger T; Kienbaum P; Kranke P
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012859. PubMed ID: 33075160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.
    Li X; Qie S; Wang X; Zheng Y; Liu Y; Liu G
    Endocrine; 2018 Dec; 62(3):535-545. PubMed ID: 30101378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the impact of efpeglenatide on cardiometabolic and safety outcomes in individuals with diabetes: a systematic review and meta-analysis.
    Qazi SU; Ansari HUH; Tharwani ZH; Altaf Z; Noman A; Ghazanfar S; Kumar S; Ansari HW; Nasir MM; Qazi S
    J Diabetes Metab Disord; 2024 Jun; 23(1):405-415. PubMed ID: 38932865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
    Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
    Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
    He L; Wang J; Ping F; Yang N; Huang J; Li Y; Xu L; Li W; Zhang H
    JAMA Intern Med; 2022 May; 182(5):513-519. PubMed ID: 35344001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison.
    Jung HN; Cho YK; Min SH; Kim HS; Kim YJ; Park JY; Lee WJ; Jung CH
    Front Endocrinol (Lausanne); 2022; 13():870722. PubMed ID: 35669682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis.
    Karrar HR; Nouh MI; Nouh YI; Nouh MI; Khan Alhindi AS; Hemeq YH; Aljameeli AM; Aljuaid JA; Alzahrani SJ; Alsatami AA; Alkredees MA; Almuqati AO; Abanmi SN; Alshehri AM
    Cureus; 2023 Sep; 15(9):e46091. PubMed ID: 37908927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
    Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M
    Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.